US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Spdr S&P Biotech Etf

82.85

-0.1050-0.13%

Volume:8.21M

Turnover:677.39M

Market Cap:5.33B

PE:4.54

High:83.50

Open:82.95

Low:80.94

Close:82.95

Loading ...

Overview Company News Filings

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

The FDA Is 'Finished' as Firings Sweep Health Agencies. Drug Stocks Are Falling. -- Barrons.com

Heard on the Street: Biotech Investors Rush for the Exits After FDA Official Resigns -- WSJ

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors

Lexaria Releases Annual Letter from the CEO

ACCESS Newswire

Beaten Down Under Biden, Big Pharma Hopes for New Chapter Under Trump -- Heard on the Street -- WSJ

Stocks ride to best month in a year as 'Red Sweep' unleashes 'animal spirits'

3 ‘Buy’ stocks and 2 ‘Hold’ stocks according to Oppenheimer

Health care sector had the most stocks with 4-week low and RSI below 30 since spring

Health care saw the largest sector weight in Q4, but the largest outflow in Q3

5 Top-Ranked ETFs to Buy on the Dip

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

XBI: Biotech ETF Is A Must Have

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/XBI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"Spdr S&P Biotech Etf","latestPrice":82.845,"timestamp":1746128962925,"preClose":82.95,"halted":0,"volume":8211103,"delay":0,"floatShares":64325000,"shares":64325000,"eps":18.23,"marketStatus":"Trading","change":-0.105,"latestTime":"05-01 15:49:24 EDT","open":82.95,"high":83.5,"low":80.935,"amount":677391035.74688,"amplitude":0.030922,"askPrice":82.86,"askSize":1440,"bidPrice":82.84,"bidSize":1276,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":82.95,"sharesOutstanding":61375000,"nav":81.834256,"aum":5022577493,"bidAskSpread":0.000283,"preHourTrading":{"tag":"盘前","latestPrice":82.74,"preClose":82.95,"latestTime":"09:16 EDT","volume":1518,"amount":126154.28562000001,"timestamp":1746105396115},"postHourTrading":{"tag":"盘后","latestPrice":83,"preClose":82.95,"latestTime":"19:58 EDT","volume":72856,"amount":6041161.0106,"timestamp":1746057504219},"volumeRatio":0.928015,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1747368000000,"strike":"80.5","timestamp":1746114456896,"price":1.35,"volume":1500,"amount":202500,"type":"+"},{"symbol":"XBI","call":false,"expireDate":1747368000000,"strike":"80.5","timestamp":1746128623044,"price":1.35,"volume":1360,"amount":183600,"type":"-"}]},"impliedVol":0.3365,"impliedVolPercentile":0.82},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":64325000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.928015,"shares":64325000,"dividePrice":0.13795,"high":83.5,"amplitude":0.030922,"preClose":82.95,"low":80.935,"week52Low":66.66,"pbRate":"--","week52High":105.47,"institutionHeld":0.8511,"latestPrice":82.845,"committee":-0.060383,"eps":18.23,"divideRate":0.001665,"volume":8211103,"delay":0,"ttmEps":18.23,"open":82.95,"prevYearClose":90.06,"prevWeekClose":80.25,"prevMonthClose":82.95,"prevQuarterClose":81.1,"fiveDayClose":80.89,"twentyDayClose":80.59,"sixtyDayClose":92.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526052630","title":"How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526052630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526052630?lang=en_us&edition=fundamental","pubTime":"2025-04-11 17:30","pubTimestamp":1744363800,"startTime":"0","endTime":"0","summary":"The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr. shake-up of the nation's health agencies and persistently high interest rates are prompting it to sink even faster than the broader market, despite so far avoiding the worst of the tariff fallout.More investors are even wondering if the whole model -- risky science, costly funding, political uncertainty and long waits for payoffs -- is simply broken. For many of the nearly 200 companies trading below their cash value, it probably is. That illustrates the pitfalls of passively investing in an index for this sector.Despite that bleak backdrop, there are still some opportunities for patient investors. After all, the U.S. is still the top spender on drugs by far. And that isn't something RFK Jr. or President Trump is likely to change.\"We lost our leadership in semiconductors, and we are close to losing that position in biotech if we don'","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491050154.USD","CGON","ALNY","CYTK","LU0471298694.HKD","LU2362541273.HKD","LU2471134523.USD","LU2462157665.USD","LU1868836914.USD","XBI","LU0256863811.USD","LU1814569148.SGD","IE0002270589.USD","IE00BJLML261.HKD","IE00BZ9MQY76.HKD","SG9999014906.USD","SG9999015945.SGD","LU0354030511.USD","SG9999017495.SGD","SG9999018865.SGD","LU0198837287.USD","BBIO","LU0061475181.USD","IE00BKVL7J92.USD","LU0203201768.USD","LU0882574139.USD","BK4505","LU1035775433.USD","LU1069344957.HKD","LU1267930730.SGD","LU1712237335.SGD","LU0640476718.USD","LU0889565916.HKD","LU1551013425.SGD","LU0256863902.USD","LU0289739699.SGD","LU2552382058.USD","LU2237443549.SGD","IE00B3T34201.USD","LU0106261372.USD","GB00BDT5M118.USD","LU0823416689.USD","LU2360106947.USD","SGXZ57979304.SGD","LU2237443978.SGD","VRTX","GILD","LU2750360641.GBP","LU2324357040.USD"],"gpt_icon":1},{"id":"2524714089","title":"The FDA Is 'Finished' as Firings Sweep Health Agencies. Drug Stocks Are Falling. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2524714089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524714089?lang=en_us&edition=fundamental","pubTime":"2025-04-02 01:46","pubTimestamp":1743529560,"startTime":"0","endTime":"0","summary":"The Trump administration began slashing jobs at U.S. public-health agencies on Tuesday morning, and the impact on the Food and Drug Administration so far has been dire, according to current and former employees.\"The FDA as we've known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed,\" former FDA Commissioner Dr. Robert Califf wrote in a LinkedIn post Tuesday morning.Drug stocks were falling Tuesday. The S&P 500 Pharmaceuticals industry index was down 2.3%, even as the S&P 500 was trading in positive territory. Shares of all of the U.S.'s largest drugmakers were taking hits: Pfizer was down 2.5%, Merck was also down 2.5%, Bristol Myers Squibb was down 2.2%, and Eli Lilly was down 1.6%. Biotech stocks were also falling, and the SPDR S&P Biotech ETF was down 2.5%.The U.S. Department of Health and Human Services had said last week that it plans to cut up to 10,000 additional jobs across publi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IE00B2B36J28.USD","LU1868836757.USD","BK4559","LU1989771016.USD","BK4588","LU0456855351.SGD","LU0306806265.USD","BK4534","IE00BJT1NW94.SGD","LU1032466523.USD","LU0061475181.USD","BMY","LU0114720955.EUR","IE0009355771.USD","LU1868836591.USD","LU0321505439.SGD","LU0237698245.USD","BK4581","LU0225284248.USD","LU0985481810.HKD","LU1868836914.USD","LU1670710661.SGD","LU0225771236.USD","IE0002141913.USD","LU1571399168.USD","LU0882574055.USD","LU1291159041.SGD","LU1718418525.SGD","XBI","IE00BSNM7G36.USD","IE00BFXG1179.USD","BK4585","LU1670711040.USD","LU2360032135.SGD","LU2125154778.USD","LU1093756168.USD","LU2125154935.USD","LU1670711123.USD","LU2133065610.SGD","LU0306807586.USD","LU1585245621.USD","LU0868494617.USD","LU0096364046.USD","LU1323610961.USD","LU1868837300.USD","LU1430594728.SGD","LU0321505868.SGD","BK4007","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2523092625","title":"Heard on the Street: Biotech Investors Rush for the Exits After FDA Official Resigns -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092625?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:05","pubTimestamp":1743433500,"startTime":"0","endTime":"0","summary":"Biotech investors are reeling after the sudden departure of Dr. Peter Marks, a pivotal figure in the U.S. Food and Drug Administration.Marks, who played a crucial role in Operation Warp Speed and championed accelerated drug approvals, announced he was stepping down, citing irreconcilable differences with Health and Human Services Secretary Robert F. Kennedy Jr.His exit sparked worry the FDA's stance on drug approvals-particularly for more innovative treatments like gene therapies and mRNA vaccines-could shift under Kennedy's leadership.On Monday, biotech stocks suffered their worst single-day drop in months. Moderna shed 13%, gene-editing company Beam Therapeutics dropped 10%, and gene therapy maker Sarepta Therapeutics fell 9%.Marks is the third top official at the FDA to leave this year, following the departures of drug chief Dr. Patrizia Cavazzoni and human foods chief Jim Jones. For the last few months, many on Wall Street have tried to stay upbeat, arguing that Dr. Marty Makary, a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4211","BK4585","BK4588","ISBC","XBI"],"gpt_icon":0},{"id":"2521257737","title":"Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521257737","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521257737?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:03","pubTimestamp":1742590980,"startTime":"0","endTime":"0","summary":"Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction. Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance. Preliminary Proxy Materials Present an Alternative Strategy to Create Significant Stockholder Value Without Extreme Dilution. Mina Sooch stated: “It is time for the stockholders to have a real voice at the Annual Meeting and new leadership on the Board. The Board has made a series of ill-advised corporate actions to entrench their position at the expense of stockholders. Stockholders should be outraged by the massive stockholder dilution, all while providing limited communication. Rather than maximizing the value of RYZUMVI—an FDA-approved, de-risked asset with zero capital requirements, extensive patient data, and significant upside—the Board has chosen to shift focus to capital-intensive, early-stage gene therapy assets with data presented in only three patients. Further","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/restore-value-slate-led-mina-210300068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4585","ARKG","XBI","BK4007","IRD","BK4544","BK4581"],"gpt_icon":0},{"id":"2518268952","title":"Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268952","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518268952?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"Figure 1 *October 24, 2024, through market close on March 7, 2025. . Notes Investor Feedback Supporting Deep Track’s Course of Action and Sharing Concerns with Company’s Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom. Highlights Dynavax’s Refusal to Reach a Constructive Resolution and Calls on Board to Stop Engaging in Petty \"Activism Defense 101\" Tactics. Questions Company’s Issuance of Expensive Convertible Notes in Recent Refinancing Instead of Using Cash on Hand. Sets Record Straight Regarding Dynavax’s Misleading Assertion That Deep Track is Seeking Control of the Board – Which is Simply False. Reiterates Need for a Refreshed Board to Drive Critical Strategic Improvements and Protect the Long-Term Interests of Shareholders. GREENWICH, Conn., March 10, 2025----Deep Track Capital, LP, , one of the largest shareholders of Dynavax Technologies Corporation  , with ownership of approximately 14.34% of the Company’s outstanding shares, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/deep-track-capital-sends-letter-120000452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","DVAX","BBIO","BK4139","BK4588","BK4585","BK4505","XBI"],"gpt_icon":0},{"id":"2507215886","title":"Lexaria Releases Annual Letter from the CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507215886","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507215886?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:15","pubTimestamp":1738246500,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive Officer  Richard Christopher as a strategic update to all stakeholders.In 2024, Lexaria made the course changing commitment to becoming an oral based drug delivery enabling technology company focused on one of the largest and fastest growing drug sectors in the world today - GLP-1. To that end, we conducted a series of human and animal studies which produced extremely encouraging pharmacokinetic, weight, blood glucose, insulin, and safety results. The success of these studies is a true testament to the effectiveness, versatility, and promise of our proprietary DehydraTECHTM technology platform within, and outside of, GLP-1.2024 R&D ResultsIn 2024, Lexaria spent virtually all of its time and efforts on conducting a series of human and animal studies which utilized our DehydraTECH technology with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-releases-annual-letter-ceo-141500696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX","XBI","BK4585","BK4007","BK4588","ACB","BK4557","BK4581"],"gpt_icon":0},{"id":"2504409485","title":"Beaten Down Under Biden, Big Pharma Hopes for New Chapter Under Trump -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2504409485","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504409485?lang=en_us&edition=fundamental","pubTime":"2025-01-20 20:00","pubTimestamp":1737374400,"startTime":"0","endTime":"0","summary":"The past two years have been punishing for the biotech and pharma space.As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a major discount to the broader market. The SPDR S&P Biotech ETF, meanwhile, was basically unchanged last year despite huge gains for innovation counterparts in the tech sector.Politics hasn't helped. After decades of wielding significant influence in Washington, the pharma lobby suffered a major blow when the Biden administration pushed through Medicare's drug-price negotiation law.Now as Donald Trump takes office, the industry is cautiously optimistic that its fortunes might finally begin to shift -- or at least not get any worse. At last week's annual JPMorgan Healthcare Conference in San Francisco, industry executives pointed to Trump's promises to cut taxes and to crack down on pharmacy-benefit managers as evidence that his policies might benefit the industry as a whole.It isn't clear whether the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","PFE","BK4588","XBI"],"gpt_icon":1},{"id":"2487594600","title":"Stocks ride to best month in a year as 'Red Sweep' unleashes 'animal spirits'","url":"https://stock-news.laohu8.com/highlight/detail?id=2487594600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487594600?lang=en_us&edition=fundamental","pubTime":"2024-11-30 04:24","pubTimestamp":1732911840,"startTime":"0","endTime":"0","summary":"Small caps, financial stocks and struggling energy names all scored big gains in the wake of Trump's electoral victory. By almost any measure, November has been a blockbuster month for U.S. stocks.Following a Republican \"Red Sweep\" on Nov. 5, optimism surrounding President-elect Donald Trump's \"America first\" agenda has revived what some have described as \"animal spirits\" in markets, helping to push major indexes like the S&P 500 and cryptocurrencies like bitcoin to record highs.So far, investors appear to be focusing on Trump's pro-business agenda, which features plans for corporate tax cuts and deregulation. While some on Wall Street have expressed concern about potential blowback from Trump's promised tariffs, so far, the market appears to be treating his trade threats as an opening salvo in a negotiation, according to Danny Kirsch, head of options at Piper Sandler, who spoke with MarketWatch on Friday.\"This deregulation America-first sort of policy for now at least is sort of reson","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","FXI","UPRO","SDS","OEF","KRE","BK4504","ESmain","BK4588","XBI","SH","BK4585","BK4559",".SPX","ICLN","SPXU","VOO","SPY","BK4534","EWW","SSO","BK4535","BK4581","OEX","IVV","BK4596"],"gpt_icon":1},{"id":"2485298273","title":"3 ‘Buy’ stocks and 2 ‘Hold’ stocks according to Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485298273","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485298273?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:58","pubTimestamp":1732291099,"startTime":"0","endTime":"0","summary":"3D_generator Oppenheimer analysts provided technical analysis for five stocks, all rated “outperform.” This is “technical color” for stocks discussed in Oppenheimer’s research call by analysts. Buy Gilead Sciences  – Uptrend  This stock has a trend with “top-down headwinds from a relatively weak biotechnology  industry.” Corning  – Uptrend  The stock is attempting to break through its April 2021 peak. “It’s also notable the stock is still trading below its year-2000 high at $113,” analysts wrote. But its bullish trend and high-momentum “argues for a definitive breakout to a new cycle high over the coming weeks to months.” McGrath RentCorp  – Reversing higher The stock has been showing improvement since its late-October breakout above its 200-day average. However, its lower momentum score “leaves something to be desired,” analysts said. Hold Alcon  – Reversing lower The stock’s trend broke below its $89 resistance , and analysts see $82 as imminent support. RxSight  – Downtrend  This st","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520290362/image_520290362.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520290362/image_520290362.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4322049-3-buy-stocks-and-2-hold-stocks-according-to-oppenheimer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4534","BK4127","LU0234570918.USD","LU1804176565.USD","XBI","BK4139","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","LU1839511570.USD","IE00BFMHRM44.USD","LU1585245621.USD","OPY","BK4581","IE0002270589.USD","BK4588","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0058720904.USD","BK4550","RXST","MGRC","BK4539","BK4585","BK4566","GLW","LU0348723411.USD","BK7094","LU0889565916.HKD","BK4198","BK4532","BK4578","GILD","BK4583","LU1066051498.USD","LU0109394709.USD","ALC.AU","LU1066053197.SGD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1571399168.USD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4512","BK4104","LU0320765992.SGD","BK4148","LU2265009873.SGD","ALC"],"gpt_icon":1},{"id":"2485260330","title":"Health care sector had the most stocks with 4-week low and RSI below 30 since spring","url":"https://stock-news.laohu8.com/highlight/detail?id=2485260330","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485260330?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:40","pubTimestamp":1732290008,"startTime":"0","endTime":"0","summary":"Two health care stocks that look “timely,” according to Krinsky:  Both Bristol Myers  – Up 38.12% in the last six months. Gilead Sciences  – Up 32.48% in the last six months.  Both have displayed bearish-to-bullish turnarounds in their charts over the last few quarters, Krinsky said. “The recent consolidations make both of them timely here, in our view.”","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251892842/image_1251892842.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251892842/image_1251892842.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4321978-health-care-sector-had-the-most-stocks-with-4-week-low-and-rsi-below-30-since-spring","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4150","LU0306806265.USD","LU1989771016.USD","LU1430594728.SGD","XLV","XBI","IHI","LU0061475181.USD","LU1261432733.SGD","LU2125154778.USD","LU0321505868.SGD","IE00BFTCPJ56.SGD","BK4534","LU1670710588.SGD","LU0225284248.USD","RSI","IE00BSNM7G36.USD","IE0002270589.USD","BK4583","IE00BKVL7J92.USD","LU0114720955.EUR","IE00B2B36J28.USD","BK4559","BK4578","LU0889565916.HKD","LU1291159041.SGD","BMY","LU1670710661.SGD","LU1839511570.USD","LU2133065610.SGD","BK4007","LU2087621335.USD","LU0320765992.SGD","BK4588","LU1718418525.SGD","LU2242646821.SGD","IE0002141913.USD","GILD","IE00B19Z3581.USD","LU1032466523.USD","LU1670711040.USD","LU0058720904.USD","LU2125154935.USD","IE00BJT1NW94.SGD","BK4585","LU1323610961.USD","BK4139","IE0009355771.USD","BK4550","LU0234570918.USD"],"gpt_icon":0},{"id":"2485147179","title":"Health care saw the largest sector weight in Q4, but the largest outflow in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2485147179","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485147179?lang=en_us&edition=fundamental","pubTime":"2024-11-21 01:03","pubTimestamp":1732122190,"startTime":"0","endTime":"0","summary":"iQoncept/iStock via Getty Images Health care (NYSEARCA:XLV) was the largest hedge fund net sector weight at the beginning of the fourth quarter. With a 17% of total net exposure and the largest “overw","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160061727/image_1160061727.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160061727/image_1160061727.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312810-health-care-saw-the-largest-sector-weight-in-q4-but-the-largest-outflow-in-q3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["IE0034235188.USD","BK4516","IE00BFXG1179.USD","LU2237443895.HKD","LU2237443622.USD","XLY","IE0004091025.USD","LU2272731600.USD","BK4585","XLK","LU1791807156.HKD","LU2237443549.SGD","LU2473716301.USD","LU2322448957.HKD","BK4581","LU2322448791.USD","XLV","LU2237443382.USD","BK4533","IE0004086264.USD","BK4504","IWV","BK4550","LU1668664300.SGD","XPH","XLF","LU2237443978.SGD","LU2237443465.HKD","LU2237438978.USD","IE00BSNM7G36.USD","LU1992135472.HKD","LU1992135399.USD","IE00B19Z3B42.SGD","BK4127","LU2272731782.SGD","LU2272731865.HKD","BK4552","IE0002270589.USD","LU0106831901.USD","IE00B19Z3581.USD","BK4588","XBI"],"gpt_icon":0},{"id":"2484080476","title":"5 Top-Ranked ETFs to Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2484080476","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484080476?lang=en_us&edition=fundamental","pubTime":"2024-11-18 23:20","pubTimestamp":1731943200,"startTime":"0","endTime":"0","summary":"The market is betting that Trump’s policies on restricting illegal immigration, enacting new tariffs, lowering taxes and reducing regulations may boost the economy but also accelerate inflation, limiting the Federal Reserve's ability to cut rates. The anticipation of greater tariff barriers and a step to move manufacturing back home is expected to drive stocks higher .The National Retail Federation  expects a strong holiday season this year, with more consumer spending in a shorter shopping season. On average, consumer spending is expected to reach a record $902 per person across gifts, food, decorations and other seasonal items. This represents an increase of about $25 per person more than last year’s figure and $16 higher than the previous record set in 2019.According to the Conference Board Holiday Spending Survey, the average U.S. consumer intends to spend $1,063 on holiday-related purchases in 2024, up 7.9% from $985 in 2023, $1,066 in 2022 and $1,022 in 2021. Strong spending will","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pxCpNGOT0tYWZp2G4ywYXQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4b62e8c333b4d6c7a8510ef8893872b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pxCpNGOT0tYWZp2G4ywYXQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4b62e8c333b4d6c7a8510ef8893872b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-top-ranked-etfs-buy-152000968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US3Y.BOND","QLD","FDN","BK4550","XBI","PSQ","BK4585","MISL","US2Y.BOND","US30Y.BOND","US12M.BOND","BK4588","US10Y.BOND","NQmain","BK4079",".IXIC","COMP","BK4539","US6M.BOND","XSD","QTEC","IDGT","MNQmain","TQQQ","BK4581","QQQ","SQQQ","QID","US7Y.BOND","US5Y.BOND"],"gpt_icon":1},{"id":"2483380416","title":"Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483380416","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483380416?lang=en_us&edition=fundamental","pubTime":"2024-11-15 02:21","pubTimestamp":1731608460,"startTime":"0","endTime":"0","summary":"EMA issues positive opinion on Leqembi, albeit for a limited patient group. Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - reversing an earlier decision not to approve the drug.The European Medicines Agency had issued a negative opinion on the drug, called Leqembi, in July, citing a side effect that involves swelling and potential bleeding in the brain.\"After re-examining its initial opinion, EMA's human-medicines committee  has recommended granting a marketing authorization to Leqembi  for treating mild cognitive impairment  or mild dementia due to Alzheimer's disease,\" the EMA said in a statement.But the drug is only being recommended for patients who are not carriers of Apoe4, a protein involved in the metabolism of fats in humans that is known to be a risk factor in Alzheimer's.Eisai had requested that the EMA revisit its negative opinion","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4581","CHMP","IE00B19Z9Z06.USD","BK4087","BIIB","BK4585","BK4533","BK4139","IE00B19Z9P08.USD","ESAIY","BK4007","LU0889565916.HKD","LU0234570918.USD","XBI","IE00B894F039.SGD","LU0109394709.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2478768667","title":"XBI: Biotech ETF Is A Must Have","url":"https://stock-news.laohu8.com/highlight/detail?id=2478768667","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478768667?lang=en_us&edition=fundamental","pubTime":"2024-10-25 03:15","pubTimestamp":1729797355,"startTime":"0","endTime":"0","summary":"Solskin As you know, biotechnology is taking a back seat in the modern stock market narrative. In my opinion, however, recent technological developments should stimulate investment in this type of asset, but I've already mentioned that before. In my view, the","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4729201-xbi-biotech-etf-a-must-have","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["BK4585","FDN","XBI","BK4581","BK4550","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"},{"date":"2024-12-23","symbol":"XBI","amount":0.002687,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-26"},{"date":"2024-09-23","symbol":"XBI","amount":0.015228,"announcedDate":"2024-09-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-23","defaultRemindTime":1727098200000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-25","payableDate":"2024-09-23","currency":"USD","dateTimestamp":1727064000000,"payDate":"2024-09-25"},{"date":"2024-06-24","symbol":"XBI","amount":0.114782,"announcedDate":"2024-06-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-26","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-26"},{"date":"2023-12-18","symbol":"XBI","amount":0.013877,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"SPDR S&P Biotech ETF","recordDate":"2023-12-21","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-19","recordDate":"2015-06-23","paymentDate":"2015-06-29","value":0.437882,"currency":"USD"},{"executeDate":"2015-09-18","recordDate":"2015-09-22","paymentDate":"2015-09-28","value":0.05004,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2015-12-29","value":0.148677,"currency":"USD"},{"executeDate":"2016-03-18","recordDate":"2016-03-22","paymentDate":"2016-03-29","value":0.057833,"currency":"USD"},{"executeDate":"2016-06-17","recordDate":"2016-06-21","paymentDate":"2016-06-27","value":0.045491,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{}}}